Patents by Inventor Richard M. van Rijn
Richard M. van Rijn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083877Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: ApplicationFiled: April 26, 2023Publication date: March 14, 2024Applicant: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
-
Patent number: 11787787Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: GrantFiled: February 2, 2021Date of Patent: October 17, 2023Assignee: Purdue Research FoundationInventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
-
Publication number: 20230293523Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: ApplicationFiled: May 22, 2023Publication date: September 21, 2023Applicant: Purdue Research FoundationInventors: Daniel P. Flaherty, Richard M. van Rijn, Val J. Watts, Jason A. Scott
-
Publication number: 20230250098Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the consumption of alcohol in a patient. These compounds may be used in treat or prevent alcoholism or an alcohol abuse disorder and show an improved pharmaceutical profile relative to other commonly used compounds.Type: ApplicationFiled: October 4, 2022Publication date: August 10, 2023Applicants: University of Health Sciences & Pharmacy in St. Louis, Purdue Research Foundation, The Trustees of Columbia University in the City of New YorkInventors: Susruta MAJUMDAR, Richard M. VAN RIJN, Soumen CHAKRABORTY, Balazs VARGA, Anna M. GUTRIDGE, Dalibor SAMES
-
Patent number: 11690844Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: GrantFiled: October 6, 2020Date of Patent: July 4, 2023Assignee: Purdue Research FoundationInventors: Daniel P. Flaherty, Richard M. van Rijn, Val J. Watts, Jason A. Scott
-
Patent number: 11667623Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: GrantFiled: April 3, 2020Date of Patent: June 6, 2023Assignee: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
-
Publication number: 20220326229Abstract: Assay for real-time simultaneous recruitment of arrestin isoforms (e.g., ?-arrestin), to a receptor, such as a G protein-coupled receptor (e.g., DOR); a biosensor; a bioarray; and a kit.Type: ApplicationFiled: February 2, 2022Publication date: October 13, 2022Applicant: Purdue Research FoundationInventors: Richard M. van Rijn, Alexander R. French, Yazan Jamal Ibrahim Meqbil
-
Publication number: 20210155614Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: ApplicationFiled: February 2, 2021Publication date: May 27, 2021Applicant: Purdue Research FoundationInventors: Richard M. Van Rijn, Mark S. Cushman, Markus Lill, Robert J. Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
-
Publication number: 20210100797Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: ApplicationFiled: October 6, 2020Publication date: April 8, 2021Applicant: Purdue Research FoundationInventors: Daniel P. Flaherty, Richard M. van Rijn, Val J. Watts, Jason A. Scott
-
Patent number: 10954224Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: GrantFiled: June 8, 2018Date of Patent: March 23, 2021Assignee: Purdue Research FoundationInventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
-
Publication number: 20200239447Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: ApplicationFiled: April 3, 2020Publication date: July 30, 2020Applicant: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
-
Publication number: 20200199111Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: ApplicationFiled: June 8, 2018Publication date: June 25, 2020Applicant: Purdue Research FoundationInventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
-
Patent number: 10662176Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: GrantFiled: July 18, 2018Date of Patent: May 26, 2020Assignee: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel P. Flaherty, Jatinder Kaur
-
Publication number: 20200031785Abstract: This present application disclosed a method for the treatment of treating pain, opioid dependence, alcohol use disorder or autism comprising the step of administering to a mammal in need thereof a therapeutically effective amount of one or more compounds of formula (I), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients. Those compounds are selective adenylyl cyclase 1 (AC1) inhibitors, which may provide an effective method of treatment for chronic/inflammatory pain, and prevent opioid dependence and/or reduce opioid dependence.Type: ApplicationFiled: September 9, 2019Publication date: January 30, 2020Applicant: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
-
Patent number: 10457653Abstract: This present application disclosed a series of selective adenylyl cyclase 1 (AC1) inhibitors, compounds having a formula or a pharmaceutically acceptable salt thereof, as a pain therapeutic. Those compounds may provide an effective method of treatment for chronic/inflammatory pain. Those compounds may also prevent opioid dependence and/or reduce opioid dependence. Both method and composition matters are within the scope of this invention.Type: GrantFiled: June 29, 2018Date of Patent: October 29, 2019Assignee: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
-
Publication number: 20190023688Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.Type: ApplicationFiled: July 18, 2018Publication date: January 24, 2019Applicant: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel P. Flaherty, Jatinder Kaur
-
Publication number: 20190002418Abstract: This present application disclosed a series of selective adenylyl cyclase 1 (AC1) inhibitors as a pain therapeutic. Those compounds may provide an effective method of treatment for chronic/inflammatory pain. Those compounds may also prevent opioid dependence and/or reduce opioid dependence. Both method and composition matters are within the scope of this invention.Type: ApplicationFiled: June 29, 2018Publication date: January 3, 2019Applicant: Purdue Research FoundationInventors: Val J. Watts, Richard M. van Rijn, Daniel P. Flaherty, Jatinder Kaur
-
Publication number: 20110046064Abstract: The present invention provides methods of treating or preventing a substance-related disorder using selective delta opioid receptor-1 (DOP-R1) agonists, delta opioid receptor-2 (DOP-R2) antagonists, and/or mu opioid receptor (MOP-R) antagonists, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist. The methods also comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and an MOP-R antagonist. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist and a MOP-R antagonist. The invention also relates to compositions containing the same. The invention also relates to methods of determining delta opioid receptor specificity of candidate agents.Type: ApplicationFiled: May 1, 2009Publication date: February 24, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Howard L. Fields, Jennifer L. Whistler, Jennifer M. Mitchell, Elyssa B. Margolis, Richard M. van Rijn